121 related articles for article (PubMed ID: 27445341)
1. RGS1 expression is associated with poor prognosis in multiple myeloma.
Roh J; Shin SJ; Lee AN; Yoon DH; Suh C; Park CJ; Huh J; Park CS
J Clin Pathol; 2017 Mar; 70(3):202-207. PubMed ID: 27445341
[TBL] [Abstract][Full Text] [Related]
2. Novel role for RGS1 in melanoma progression.
Rangel J; Nosrati M; Leong SP; Haqq C; Miller JR; Sagebiel RW; Kashani-Sabet M
Am J Surg Pathol; 2008 Aug; 32(8):1207-12. PubMed ID: 18580492
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of RGS1 and mTOR Immunohistochemical expression in Egyptian multiple myeloma patients; A single center study.
Hafez N; Refaat L; ElGebaly OK; Elhariry HM; Ghareeb M; Fathalla LA
PLoS One; 2023; 18(7):e0288357. PubMed ID: 37437037
[TBL] [Abstract][Full Text] [Related]
4. High nuclear expression of Twist1 in the skeletal extramedullary disease of myeloma patients predicts inferior survival.
Yang JZ; Lian WG; Sun LX; Qi DW; Ding Y; Zhang XH
Pathol Res Pract; 2016 Mar; 212(3):210-6. PubMed ID: 26774288
[TBL] [Abstract][Full Text] [Related]
5. PLP2 Expression as a Prognostic and Therapeutic Indicator in High-Risk Multiple Myeloma.
Bai H; Zhu Y; Xu P; Chen B
Biomed Res Int; 2020; 2020():4286101. PubMed ID: 32596309
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA-15a/16-1 cluster located at chromosome 13q14 is down-regulated but displays different expression pattern and prognostic significance in multiple myeloma.
Li F; Xu Y; Deng S; Li Z; Zou D; Yi S; Sui W; Hao M; Qiu L
Oncotarget; 2015 Nov; 6(35):38270-82. PubMed ID: 26516702
[TBL] [Abstract][Full Text] [Related]
7. Single-Cell Transcriptome Analysis Reveals RGS1 as a New Marker and Promoting Factor for T-Cell Exhaustion in Multiple Cancers.
Bai Y; Hu M; Chen Z; Wei J; Du H
Front Immunol; 2021; 12():767070. PubMed ID: 34956194
[TBL] [Abstract][Full Text] [Related]
8. Cyclin kinase subunit 1B nuclear expression predicts an adverse outcome for patients with relapsed/refractory multiple myeloma treated with bortezomib.
Chen MH; Qi C; Reece D; Chang H
Hum Pathol; 2012 Jun; 43(6):858-64. PubMed ID: 22047644
[TBL] [Abstract][Full Text] [Related]
9. Adverse prognostic impact of bone marrow microvessel density in multiple myeloma.
Lee N; Lee H; Moon SY; Sohn JY; Hwang SM; Yoon OJ; Youn HS; Eom HS; Kong SY
Ann Lab Med; 2015 Nov; 35(6):563-9. PubMed ID: 26354343
[TBL] [Abstract][Full Text] [Related]
10. Identification and validation of potential prognostic lncRNA biomarkers for predicting survival in patients with multiple myeloma.
Zhou M; Zhao H; Wang Z; Cheng L; Yang L; Shi H; Yang H; Sun J
J Exp Clin Cancer Res; 2015 Sep; 34(1):102. PubMed ID: 26362431
[TBL] [Abstract][Full Text] [Related]
11. Features of extramedullary disease of multiple myeloma: high frequency of p53 deletion and poor survival: a retrospective single-center study of 834 cases.
Deng S; Xu Y; An G; Sui W; Zou D; Zhao Y; Qi J; Li F; Hao M; Qiu L
Clin Lymphoma Myeloma Leuk; 2015 May; 15(5):286-91. PubMed ID: 25640025
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical analysis of NOTCH1 and JAGGED1 expression in multiple myeloma and monoclonal gammopathy of undetermined significance.
Skrtić A; Korać P; Krišto DR; Ajduković Stojisavljević R; Ivanković D; Dominis M
Hum Pathol; 2010 Dec; 41(12):1702-10. PubMed ID: 20800871
[TBL] [Abstract][Full Text] [Related]
13. Neuron-glial antigen 2 overexpression in hepatocellular carcinoma predicts poor prognosis.
Lu LL; Sun J; Lai JJ; Jiang Y; Bai LH; Zhang LD
World J Gastroenterol; 2015 Jun; 21(21):6649-59. PubMed ID: 26074703
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of cyclooxygenase-2 in multiple myeloma: association with reduced survival.
Cetin M; Buyukberber S; Demir M; Sari I; Sari I; Deniz K; Eser B; Altuntas F; Camci C; Oztürk A; Turgut B; Vural O; Unal A
Am J Hematol; 2005 Nov; 80(3):169-73. PubMed ID: 16247750
[TBL] [Abstract][Full Text] [Related]
15. The prognostic value of diagnosing concurrent multiple myeloma in immunoglobulin light chain amyloidosis.
Dinner S; Witteles W; Witteles R; Lam A; Arai S; Lafayette R; George TI; Schrier SL; Liedtke M
Br J Haematol; 2013 May; 161(3):367-72. PubMed ID: 23432783
[TBL] [Abstract][Full Text] [Related]
16. Ataxia-telangiectasia-mutated protein kinase levels stratify patients with pancreatic adenocarcinoma into prognostic subgroups with loss being a strong indicator of poor survival.
Kamphues C; Bova R; Bahra M; Klauschen F; Muckenhuber A; Sinn BV; Warth A; Goeppert B; Endris V; Neuhaus P; Weichert W; Stenzinger A
Pancreas; 2015 Mar; 44(2):296-301. PubMed ID: 25423555
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic and prognostic significance of CD200 expression and its stability in plasma cell myeloma.
Douds JJ; Long DJ; Kim AS; Li S
J Clin Pathol; 2014 Sep; 67(9):792-6. PubMed ID: 24958785
[TBL] [Abstract][Full Text] [Related]
18. Expression of pyruvate dehydrogenase is an independent prognostic marker in gastric cancer.
Sun XR; Sun Z; Zhu Z; Guan HX; Li CY; Zhang JY; Zhang YN; Zhou H; Zhang HJ; Xu HM; Sun MJ
World J Gastroenterol; 2015 May; 21(17):5336-44. PubMed ID: 25954108
[TBL] [Abstract][Full Text] [Related]
19. Vitronectin significantly influences prognosis in osteosarcoma.
Shi K; Lan RL; Tao X; Wu CY; Hong HF; Lin JH
Int J Clin Exp Pathol; 2015; 8(9):11364-71. PubMed ID: 26617861
[TBL] [Abstract][Full Text] [Related]
20. Protein expression of HER2, 3, 4 in gastric cancer: correlation with clinical features and survival.
He XX; Ding L; Lin Y; Shu M; Wen JM; Xue L
J Clin Pathol; 2015 May; 68(5):374-80. PubMed ID: 25731189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
